
Qualio is a purpose-built quality and compliance platform for life sciences companies operating in complex, high-stakes regulatory environments. Medical device, SaMD, biotech, and pharma teams use Qualio to replace fragmented eQMS tools, spreadsheets, and consultant-driven audits with a single, validated system that delivers continuous audit and inspection readiness.
Qualio combines a modern eQMS with Compliance Intelligence—an AI-driven layer that continuously evaluates how well real operating data aligns with regulatory requirements. Instead of treating audits as one-off events, teams gain always-on visibility into compliance coverage, risk exposure, and readiness across FDA, ISO, EU MDR, GxP, and software-intensive standards.
Core quality workflows—document control, training, CAPA, change management, supplier quality, and design controls—are directly connected to regulatory obligations and objective evidence. Deep integrations with Jira, Azure DevOps, GitHub, TestRail, and Salesforce automatically capture proof from development and operational systems, eliminating manual evidence gathering and reducing compliance drag on engineering teams.
Compliance Intelligence runs multi-standard gap analysis in under an hour, flags emerging risks before they become findings or 483s, and maps reusable evidence across frameworks to accelerate submissions and market expansion. All insights are explainable and traceable back to specific clauses and internal policies, supporting validation and audit expectations.
The result: audit readiness in weeks instead of months, fewer fire drills, faster launches, and lower long-term compliance cost. Qualio turns compliance from a reactive burden into a predictable, scalable system.
Learn more

AlisQI is a cloud-based Quality Management platform built for process and batch manufacturers who want to move beyond reactive firefighting toward stable, predictable operations while maintaining full compliance control.
Rather than organizing quality around static documents and isolated events, AlisQI was designed as a data-first system. Quality, laboratory, and production data are structured and connected in a shared operational backbone. This gives cross-functional teams early visibility into deviations, faster response times, and greater confidence in product integrity and daily execution.
The platform combines configurable quality modules, including document control, training, deviations, CAPA, audits, risk management, supplier quality, SPC, and EHS, with targeted, ready-to-use Solvers. Solvers integrate forms, workflows, dashboards, and business logic to address specific operational problems without unnecessary scope.
Because the system is built on structured data, manufacturers can apply practical AI within workflows, from automated COA extraction to conversational access to quality data and pattern detection across incidents.
Solvers are production-ready from day one and evolve as processes, products, or plants change. This progression does not require custom development or disruptive IT projects.
Manufacturers use AlisQI to harmonize quality practices across sites, reduce waste and rework, strengthen audit readiness, accelerate root cause analysis, and connect shop-floor and lab data directly to quality decision-making across industries including chemicals, plastics, packaging, food and beverage, personal care, automotive, and industrial manufacturing.
Learn more
BIOVIA Discovery Studio
The biopharmaceutical sector today is characterized by its intricacy, driven by increasing demands for enhanced specificity and safety, the emergence of new treatment classes, and the complexity of disease mechanisms. To navigate this intricate landscape, a profound comprehension of therapeutic dynamics is essential. Advanced modeling and simulation techniques offer a distinctive approach to investigate biological and physicochemical phenomena at the atomic scale. This methodology not only informs physical experimentation but also expedites the drug discovery and development phases. BIOVIA Discovery Studio integrates more than three decades of peer-reviewed research with cutting-edge in silico methodologies, including molecular mechanics, free energy assessments, and biotherapeutics developability, all within a unified framework. By equipping researchers with a comprehensive suite of tools, it facilitates a deeper examination of protein chemistry, thereby accelerating the discovery of both small and large molecule therapeutics, from Target Identification all the way through to Lead Optimization. Ultimately, this synergy of research and technology underscores the vital role of innovative tools in transforming biopharmaceutical advancements.
Learn more
Atomwise
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Learn more